Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

the agreement, we obtained the exclusive U.S. rights to NexMed's topically applied alprostadil cream for the treatment of erectile dysfunction. We paid a license fee of $0.5 million which was recognized in R&D expense in the fourth quarter of 2007. The increase in our R&D activities, excluding the $0.5 million payment to NexMed, was $3.8 million, or 52.7%, which was mainly due to costs incurred in connection with clinical studies for two new oral contraceptives. We completed the enrollment of the first clinical study for a low-dose oral contraceptive in July 2007 and we completed enrollment of another clinical study for an oral contraceptive in December 2007.

Net Interest Expense

Interest expense, less interest income ("Net Interest Expense") for the quarter ended December 31, 2007 was $27.3 million, a decrease of $32.9 million, or 54.7%, from $60.2 million in the prior year quarter. The quarter ended December 31, 2007 included a $1.6 million write-off of deferred loan costs associated with an optional prepayment of $90.0 million under our senior secured credit facility. In the quarter ended December 31, 2006, the Company paid a premium in the amount of $18.4 million in connection with the optional redemption of $210.0 million of our 8.75% Senior Subordinated Notes ("Notes"). As a result of the optional redemption, the quarter ended December 31, 2006 included an $8.0 million write-off of deferred loan costs associated with the Notes. The quarter ended December 31, 2006 also included a $1.1 million write- off of deferred loan costs associated with an optional prepayment of $50.0 million under our senior secured credit facility. Excluding the premium payment and the write-offs of deferred loan costs, Net Interest Expense decreased $7.0 million, or 21.7%, in the current quarter. The decrease was primarily the result of reductions in outstanding debt which reduced the weighted average debt outstanding in the quarter ended December 31, 2007, as compared to
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Aligns Operations for Enhanced Performance, DECATUR, ... (NYSE: ADM ) chairman, chief executive ... organizational restructure of the,Company, designed to enhance ... responsibility for long-term success. The reorganization creates ...
... oximetry technology to significantly reduce, false alarms without missing ... ... Aug. 22 Masimo (Nasdaq:,MASI), the inventor of Pulse CO-Oximetry ... partnership with Apria,Healthcare to provide pulse oximetry products and accessories ...
... symbol: SBS, - Canadian Biotechnology Company confirms commercial ... AI Milano variant and clarifies status of native ... - SemBioSys Genetics Inc.,(TSX:SBS), a biotechnology company developing ... diseases, today updated a release,issued on July 12, ...
Cached Biology Technology:ADM Reorganizes Operations 2ADM Reorganizes Operations 3ADM Reorganizes Operations 4Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Company's Home Health Care Business 2Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Company's Home Health Care Business 3SemBioSys updates Apo AI development program 2SemBioSys updates Apo AI development program 3SemBioSys updates Apo AI development program 4
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... sole proprietors of their nests, some tropical species time ... a 150-year-old evolutionary mystery, says Queens University Biology professor ... confirms one of Charles Darwins more controversial theories ... many experts that different species can arise, unhindered, ...
... The Shifting Baselines Toolset is presented to the public and ... , When: Public symposium 1pm to 5:15pm, Wednesday 14th November ... city campus. , The meeting will be launched with a ... for interviews on the 14th and on other days by ...
... 13, 2007) A major study that will provide a ... be conducted by the La Jolla Institute for Allergy ... The five-year study, funded by the National Institute ... National Institutes of Health, could lead to revolutionary new ...
Cached Biology News:'Time-sharing' tropical birds key to evolutionary mystery 2How much fish have we got? 2How much fish have we got? 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4
Human ROR1 Affinity Purified Polyclonal Ab...
Ultra-sensitive, non-radioactive measurement of COX-I and COX-II activity...
Phospho-p70 S6 Kinase (T229) Affinity Purified PAb...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Biology Products: